Skip to main content

Table 2 Most common adverse events

From: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

  Grade 1–2 Grade 3 Grade 4
n % n % n %
Hematologic
 Neutropenia 10 12.0 19 22.9 9 10.8
 Anemia 24 28.9 4 4.8 0 0.0
 Thrombocytopenia 1 1.2 0 0.0 0 0.0
 Febrile neutropenia 0 0.0 4 4.8 1 1.2
Non-hematologic
 Increased ALT concentration 1 1.2 0 0.0 0 0.0
 Increased AST concentration 1 1.2 0 0.0 0 0.0
 Asthenia/Fatigue 61 73.5 11 13.3 0 0.0
 Nausea 46 55.4 4 4.8 0 0.0
 Diarrhea 63 75.9 6 7.2 0 0.0
 Vomiting 28 33.8 1 1.2 0 0.0
 Mucositis 44 53.0 8 9.6 0 0.0
 Peripheral edema 2 2.4 0 0.0 0 0.0
 Peripheral sensory neuropathy 15 18.1 5 6.0 0 0.0
 Dry skin 11 13.2 0 0.0 0 0.0
 Left ventricular dysfunction 2 2.4 1 1.2 0 0.0